SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes - Wikidata - awgldk - TriplyDB

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

http://www.wikidata.org/entity/Q34460468

about

Prescribing for patients on dialysis Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus Preclinical and Clinical Studies for Sodium Tungstate: Application in Humans.Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.

P2860

Q26752999-A00663ED-04C7-46AE-B54C-3A0FC5955B48 Q33871321-C3CA4BF1-0FF6-4DB1-8887-CBF5B4233284 Q35618949-7737E4E5-8F81-4CF7-8FBF-CDF0F6623C4C Q36303346-A0081974-7E3D-46A4-90DB-1D0EA111B51E Q39023661-3BC025B2-F579-4828-90AD-359426DBD203 Q40382882-BB40A63C-87F3-4717-B07D-61170A73E56B Q48234943-022BA201-02C4-4EF4-8E08-34B92FF73CDF

P2860

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

http://www.wikidata.org/entity/Q34460468

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@ast

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@en

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@nl

type

label

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@ast

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@en

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@nl

prefLabel

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@ast

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@en

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@nl

P1433

Q34460468-E16651CF-0E34-4849-BB7B-2B6E4FA0BE5D

P1476

Q34460468-586795C9-1D5D-492F-A8E9-6C608C8FCF65

P2093

Q34460468-02DDE63E-9AB4-433A-A524-66C40DD2CBF9

Q34460468-A7397406-BD04-4362-BED1-E76AFCFBC041

P2860

Q34460468-1CB25218-0C7E-4521-A435-4FC4C78A8589

Q34460468-1F0E86D8-AAD7-496C-8327-413AC9455F69

Q34460468-27C2D393-EABA-459D-BC71-CA824CAF31CE

Q34460468-28B76C35-2DA6-4D70-AC97-4B8FD8ABB8F6

Q34460468-2C4E93AF-4A39-4593-ADE4-D0CE59422D00

Q34460468-3380C216-9EE3-48E2-BD21-8769C44FE132

Q34460468-3A757815-F753-48A7-9771-08FDC317AFCF

Q34460468-4422195D-527E-44B9-88BD-6FD8D2B53937

Q34460468-45A9EB35-E07A-4115-AC91-7AC3F39F6D06

Q34460468-4F14C6FF-3A67-460D-B868-06A9E7D6999D

P304

Q34460468-113466A0-274D-4473-80E2-F701D7F1432B

P31

Q34460468-117727A1-549D-49FF-98B5-88ED8529468C

P356

Q34460468-D6292FF1-D0D5-4862-85C4-4FEB487972A6

P433

Q34460468-45F4B954-0C13-42F8-A7A6-1B7186733AE0

P478

Q34460468-102981B4-71AB-4DBA-AAFB-0DB1EEE230AF

P50

Q34460468-0B06A4C3-14BF-40C5-B3DC-0146A91095F8

P577

Q34460468-F1F5463B-401E-4423-9987-348BA21AEDC8

P698

Q34460468-53677D5C-D0B2-4827-8BB3-6BBF2895C8C0

P921

Q34460468-C78AA535-2D35-42E6-8521-48F0EF9E6729

P932

Q34460468-C96571F1-27B6-4EA9-81AC-3604107C7012

P356

P1433

Australasian Medical Journal

P1476

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

@en

P2093

Carol Pollock

http://www.w3.org/2001/XMLSchema#string

Robert G Moses

http://www.w3.org/2001/XMLSchema#string

P2860

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

Effects of intensive glucose lowering in type 2 diabetes

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

SGLT2 mediates glucose reabsorption in the early proximal tubule.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

[Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.

P304

405-415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4066/AMJ.2014.2181

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Colagiuri

P577

2014-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25379062

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4221776

http://www.w3.org/2001/XMLSchema#string